Finally, the tumor vasculature has also been targeted by OVV-CXCR4-A-mFc, a VV expressing a CXCR4 antagonist, which is directed against the VEGF-induced pro-angiogenic CXCL12/CXCR4 signaling pathway in human breast tumor cells. This evidence concerns the gene CXCL12 and neoplasm.